HONG KONG (Reuters) - Asian share markets mostly rose on Tuesday as global investors applauded successful trial data for a coronavirus vaccine, although expected delays to any mass roll-out took the gloss off early gains.
European futures trading during the Asian session were indicating a weaker open of at least 1.2%, while U.S. futures showed a potential fall of at least 0.5% after Monday’s steep market gains.
The positive tone in Asian equities came after Pfizer Inc said its COVID-19 vaccine, developed with German partner BioNTech SE, was more than 90% effective in preventing infection, marking the first successful results from a large-scale clinical trial.
Major Asian markets soared on the vaccine news before weakening later in the session. Japan's Nikkei 225 ended up nearly 0.3% after being 1.1% higher in early trading, touching a 29-year high.
Australia's S&P/ASX 200 closed 0.66% higher after trading up as much as 1.6%, while Hong Kong's Hang Seng index was at 0.77% in the afternoon after rising 1% in early trade. Singapore's Straits Times gained 2.94% to take the index to its highest point since June.
Despite the optimistic tone across the region, there was some weakness in China, with the CSI300 Index slipping 0.17%.
Peringatan: Pendapat yang disampaikan sepenuhnya merupakan milik penulis dan tidak mencerminkan posisi resmi Followme. Followme tidak bertanggung jawab atas keakuratan, kelengkapan, atau keandalan informasi yang disediakan, serta tidak bertanggung jawab atas tindakan apa pun yang diambil berdasarkan konten ini, kecuali dinyatakan secara tertulis.
Tinggalkan pesan Anda sekarang